Purdue Research Foundation

Industry-University Cooperation Foundation Hanyang University

Pepsico, Inc.

Yoon Yeo

Peisheng Xu

Karen Liu

Eun Jung Cho

Gaurav Bajaj

Wanqing Liu

Kinam Park

Robert Samuel Langer

Daniel S Kohane

Peter S Given

Chi Hwan Lee

Robert S Langer, Jr

Osman Basaran

Dong Rip Kim

Robert Langer

Simseok Yuk

Joonyoung Park

Alvin Un-Teh Chen

Bo Sun

Jun Xu

The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis.

Process and composition matter of nanoparticle formulation for systemic treatment of sepsis

Drug delivery devices that have a flexible film, an array of nanoscopic, porous needles attached to a surface of the flexible film, and a therapeutic drug cargo loaded onto the needles. The drug delivery device may be applied to living tissue such that the surface of the flexible film contacts the living tissue and some or all of the needles are inserted into the tissue. The flexible film may then be dissolved while leaving the needles inserted in the tissue. The needles degrade in the living tissue over time causing release of the therapeutic drug cargo loaded onto the needles.

Drug delivery devices and methods of fabrication and use therefor

The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targeted drug delivery to cancerous cells or tissues via E-selectin- or P-selectin-mediated transcytosis. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers.

Quinic acid-modified nanoparticles and uses thereof

The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).

siRNA compositions that specifically down regulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease

siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)

A carrier free nanoparticle formulation with good circulation stability is made for anticancer drug delivery. Nanocrystals crystallized in the medium containing Pluronic F-127 then coated with albumin (Cim-F-Alb) had the smallest size and the most native albumin, and showed most favorable cell interaction profiles and better stability than commercial albumin based Abraxane formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved paclitaxel (PTX).

Carrier-free nanoparticles

The present disclosure provides a polymer comprising a derivative of chitosan, wherein the derivative is zwitterionic, as well as methods of using the polymer. In addition, the present disclosure provides a nanoparticle structure comprising a derivative of chitosan and a dendrimer, as well as methods of utilizing the nanoparticle structure.

Chitosan derivatives for inactivation of endotoxins and surface protection of nanoparticles

A complex coacervate delivery system is provided which encapsulates lipophilic nutrients such as, for example, fish oils high in omega-3 fatty acids. The complex coacervate delivery system protects the lipophilic nutrient from degradation, e.g., oxidation and hydrolysis, and also reduces or eliminates the unpleasant taste and odor of the lipophilic nutrient. The complex coacervate delivery system upon ingestion is operative to substantially release the lipophilic nutrient in the lower gastrointestinal tract in a pH-controlled manner. The complex coacervate delivery system may be included in a food or beverage product having a pH value within the range of about 1.5 to about 5.0.

Delivery and controlled release of encapsulated lipophilic nutrients

A method for generating a plurality of drug-containing microcapsules employs one or more atomizers to form the microcapsules by the phenomenon of solvent exchange. A plurality of microdroplets of an aqueous solution is contacted with a plurality of microdroplets containing a polymer dissolved in a hydrophilic solvent under conditions whereby the polymer solution envelops the aqueous microdroplet. Exchange of solvent molecules between the aqueous core and its polymer-containing shell deposits the polymer as a membrane around the aqueous core. A preferred atomizer is a coaxial ultrasonic atomizer. Microcapsules can be generated in air as well as when submersed in a collection bath. Desired properties of the microcapsules, e.g., controlled release, can be achieved by providing protective excipients within the aqueous core, providing a hydrophilic polymer capable of undergoing a sol-to-gel transition within the aqueous core, optimizing selection of the polymer solvent, adjusting relative flow rates, and the like.

Microencapsulation using ultrasonic atomizers

A solvent exchange method is employed to provide microencapsulated compositions, such as microcapsules of pharmaceutical preparations. The method is based on an exchange of water and a hydrophilic organic solvent, whereby a decline in solvent quality for the organic solvent causes a polymer dissolved therein to be deposited onto an aqueous core. Optimal results are rationalized in terms of a balance of water solubility and surface tension for the organic solvent. In a preferred embodiment, microcapsules of selected drugs are formed by contacting microdroplets of an aqueous solution containing the drug with the organic solvent containing a polymer dissolved therein. A preferred method employs biodegradable poly(lactic acid-co-glycolic acid) (PLGA) dissolved in acetic acid, ethyl acetate, methyl acetate, or ethyl formate, to form a PLGA membrane around an aqueous drug core. The method is particularly attractive for encapsulating protein-based drugs without substantial denaturation.

Growing community of inventors

West Lafayette, IN, United States of America

Yoon Yeo